Compare FORTY & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORTY | FTRE |
|---|---|---|
| Founded | 1985 | 1996 |
| Country | Israel | United States |
| Employees | 19337 | 14000 |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1998 | 2023 |
| Metric | FORTY | FTRE |
|---|---|---|
| Price | $114.99 | $19.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.06 |
| AVG Volume (30 Days) | 2.1K | ★ 1.2M |
| Earning Date | 05-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.09 |
| P/E Ratio | $36.65 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $102.01 | $8.31 |
| 52 Week High | $190.56 | $21.39 |
| Indicator | FORTY | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 56.37 |
| Support Level | $109.49 | $15.77 |
| Resistance Level | $119.68 | $21.25 |
| Average True Range (ATR) | 1.67 | 0.96 |
| MACD | 0.09 | 0.12 |
| Stochastic Oscillator | 34.78 | 72.21 |
Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.